# Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

> **NCT07241793** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 96 (estimated)

## Conditions studied

- Urothelial Carcinoma
- Advanced Urothelial Carcinoma
- Urothelial Carcinoma Recurrent

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Trastuzumab Rezetecan

## Key facts

- **NCT ID:** NCT07241793
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2028-07-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241793, "Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07241793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*